National Institutes of Health: Fallopian Tube Neoplasms trials

The registry lists 71 Fallopian Tube Neoplasms studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 40 have results posted.

Early Phase 1 1Phase 1 26Phase 2 40Phase 3 8No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
• Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian CancerActive, not recruitingNCT05276973Phase 1Results posted
• Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid TumorsActive, not recruitingNCT04616534Phase 1Results posted
• Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal CancerActive, not recruitingNCT04034927Phase 2Results posted
• Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT03206047Phase 1/2Results posted
• Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerTerminatedNCT02948426Phase 1Results posted
• Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02839707Phase 2/3Results posted
• Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02627443Phase 1Results posted
• Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02595892Phase 2Results posted
• Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerActive, not recruitingNCT02502266Phase 2/3Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02498600Phase 2Results posted
• Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02446600Phase 3Results posted
• Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerActive, not recruitingNCT02345265Phase 2Results posted
• TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsActive, not recruitingNCT02142803Phase 1Results posted
• Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02101775Phase 2Results posted
• Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal CancerTerminatedNCT01681368Phase 2Results posted
• Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal CancerCompletedNCT01313078Phase 2Results posted
• Phase II ABT-888 With CyclophosphamideCompletedNCT01306032Phase 2Results posted
• SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or CarboplatinTerminatedNCT01200797Phase 2Results posted
• RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01175343Phase 2Results posted
• Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerActive, not recruitingNCT01167712Phase 3Results posted
• Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast CancerActive, not recruitingNCT01116648Phase 1/2Results posted
• Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube CancerActive, not recruitingNCT01081262Phase 3Results posted
• Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal CancerActive, not recruitingNCT01012817Phase 1/2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or CisplatinCompletedNCT00993616Phase 2Results posted
• Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT00565851Phase 3Results posted
• Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT00445549Phase 2Results posted
• VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00436501Phase 1/2Results posted
• Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal CancerCompletedNCT00436215Phase 2Results posted
• Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00429793Phase 2Results posted
• Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue SarcomaCompletedNCT00390234Phase 2Results posted
• Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00388037Phase 2Results posted
• Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT00334893Phase 2Results posted
• Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT00278343Phase 2Results posted
• AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00275028Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00262847Phase 3Results posted
• Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian CancerCompletedNCT00182767Phase 1/2Results posted
• Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00096200Phase 2Results posted
• Erlotinib Plus Carboplatin and Paclitaxel in Ovarian CarcinomaCompletedNCT00059787Phase 2Results posted
• Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00041080Phase 3Results posted
• Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnNCT06393751Phase 1/2
• Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersActive, not recruitingNCT05691504Phase 1
• Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554328Phase 2
• Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyWithdrawnNCT05295589Phase 2
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerActive, not recruitingNCT04092270Phase 1
• Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid TumorsTerminatedNCT03189108
• Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02042430Early Phase 1
• 18F-CP18 Imaging Studies for Cancer Treatment With BirinapantWithdrawnNCT01766622Phase 2
• Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT01749397Phase 1
• Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT01459380Phase 1
• Endoxifen in Adults With Hormone Receptor Positive Solid TumorsCompletedNCT01273168Phase 1
• Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s CancersCompletedNCT01237067Phase 1
• Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01074411Phase 1
• Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00989651Phase 1
• Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum ChemotherapyCompletedNCT00602277Phase 1
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00126542Phase 2
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube CancersCompletedNCT00086567
• Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)CompletedNCT00085358Phase 1
• Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00079430Phase 1
• Immunotoxin Therapy in Treating Patients With Advanced Solid TumorsCompletedNCT00066651Phase 1
• Gefitinib in Treating Patients With Cervical CancerCompletedNCT00049556Phase 2
• Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential TumorCompletedNCT00039585Phase 2
• Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal CancerCompletedNCT00019552Phase 2
• Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00019461Phase 2
• Immunotoxin Therapy in Treating Patients With Advanced CancerCompletedNCT00006981Phase 1
• Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00006942Phase 2
• SU5416 and Carboplatin to Treat Ovarian CancerCompletedNCT00006155Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1